Fonarow G C
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los Angeles, CA, USA.
Rev Cardiovasc Med. 2001;2 Suppl 2:S32-5.
The therapeutic goals for patients hospitalized with acute decompensated heart failure are to reverse acute hemodynamic abnormalities, relieve symptoms, and provide the ability to initiate early treatment, which will decrease disease progression and improve long-term survival. The use of nesiritide on top of standard care, such as diuretic therapy, has been proven to lead to meaningful clinical benefits in a broad range of acutely decompensated heart failure patients. Nesiritide is an attractive therapeutic option because of its more rapid and sustained hemodynamic profile with less adverse effects than alternative heart failure treatments, such as nitroglycerine or dobutamine. The use of nesiritide represents an entirely new treatment approach to reverse acutely decompensated heart failure and to facilitate optimization of the heart failure medical regimen.
因急性失代偿性心力衰竭住院患者的治疗目标是逆转急性血流动力学异常、缓解症状，并具备启动早期治疗的能力，这将减少疾病进展并提高长期生存率。在标准治疗（如利尿剂治疗）基础上加用奈西立肽，已被证明可使广泛的急性失代偿性心力衰竭患者获得显著的临床益处。奈西立肽是一种有吸引力的治疗选择，因为与其他心力衰竭治疗药物（如硝酸甘油或多巴酚丁胺）相比，其血流动力学表现更迅速、更持久，且不良反应更少。使用奈西立肽代表了一种全新的治疗方法，用于逆转急性失代偿性心力衰竭并促进心力衰竭药物治疗方案的优化。
